AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Predicting Immunotherapy Response and Survival of Lung Cancer Patients Using Artificial Intelligence and Radiomics (Radiology-AI-Lung)

Recruitingn/aAges 18 Years - anyAllUnion Hospital, Tongji Medical College, Huazhong …
💬

In plain words

What the trial is, and whether it could suit you

CT imaging data from lung cancer (NSCLC and SCLC) patients prior to the initiation of immunotherapy (and possibly also after treatment) will be collected. The processing pipeline includes automatic tumor segmentation, radiomics feature extraction, feature selection, and construction of a classification model.

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients were treated for lung cancer in Wuhan Union Hospital from July 2025 to July 2026; 2. Aged \> 18 years old; 3. At least one CT scan before treatment; 4. Tissue biopsy pathological examination confirmed the diagnosis of the above tumors. Exclusion criteria: 1. Poor image quality; 2. Incomplete clinical data or loss of follow-up; 3. Presence of another primary malignancy other than lung cancer; 4. Unclear pathological diagnosis.
💊

What it tests

  • Not listed
📍

Where

1 site
Union Hospital,Tongji Medical College,Huazhong University of Science and Technology
Wuhan, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy